Enovis Corp (ENOV)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enovis Corp (ENOV) Stock Forecast
Analysts expect Enovis (ENOV) to earn $3.70 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.34B. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 15.4% |
| Buy | 10 | 76.9% |
| Hold | 1 | 7.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 6.5% and revenue estimates rise 4.7%.
- Fiscal year ending Dec 31, 2026
- $3.70
- EPS consensus, revenue $2.34B
- Fiscal year ending Dec 31, 2027
- $3.46
- EPS consensus, revenue $2.45B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.70 | $3.64 to $3.75 | 13 | $2.34B | $2.33B to $2.34B | 13 |
| Dec 31, 2027 | $3.46 | $3.18 to $3.94 | 13 | $2.45B | $2.42B to $2.47B | 13 |
Quarterly Estimates
The EPS consensus falls from $1.06 for the quarter ending Dec 31, 2026 to $0.87 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.06 | $0.97 to $1.13 | 15 | $618.46M | $589.86M to $643.65M | 15 |
| Mar 31, 2027 | $0.87 | $0.82 to $0.97 | 7 | $612.92M | $606.90M to $620.10M | 4 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.6% from $3.64.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.70 | $3.63 | $3.63 | $3.64 | $3.64 | +1.7% |
| Fiscal year ending Dec 31, 2027 | $3.46 | $3.54 | $3.59 | $3.69 | $4.06 | -14.6% |
| Quarter ending Mar 31, 2027 | $0.87 | $0.87 | $0.89 | $0.89 | $1.00 | -12.8% |
Frequently Asked Questions About ENOV
What is the ENOV stock forecast?
Consensus analyst estimates put Enovis's EPS at $3.70 for the fiscal year ending Dec 31, 2026, on revenue of $2.34B. The consensus rating from 13 analysts is Buy.
How do analysts rate ENOV stock?
Of 13 analysts covering Enovis, 2 rate it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ENOV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.70, with estimates from $3.64 to $3.75 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.46, with estimates from $3.18 to $3.94 from 13 analysts.
What revenue do analysts expect from Enovis next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.34B, with estimates from $2.33B to $2.34B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.45B, with estimates from $2.42B to $2.47B.
How many analysts cover ENOV?
13 analysts rate Enovis stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ENOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors